Charles Zhu
Stock Analyst at LifeSci Capital
(2.53)
# 2,065
Out of 4,818 analysts
24
Total ratings
47.62%
Success rate
13.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPTX Repare Therapeutics | Downgrades: Market Perform | n/a | $1.28 | - | 1 | Dec 13, 2024 | |
| TNGX Tango Therapeutics | Maintains: Buy | $18 → $8 | $1.49 | +436.91% | 3 | Nov 7, 2024 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $1.71 | +601.75% | 4 | Nov 7, 2023 | |
| MRUS Merus | Maintains: Buy | $46 → $48 | $41.90 | +14.56% | 6 | Aug 8, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $72.70 | -22.97% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $4.20 | +423.81% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $4.48 | +480.36% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $18.84 | +69.90% | 3 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $12.46 | +12.36% | 2 | May 5, 2022 |
Repare Therapeutics
Dec 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.28
Upside: -
Tango Therapeutics
Nov 7, 2024
Maintains: Buy
Price Target: $18 → $8
Current: $1.49
Upside: +436.91%
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $1.71
Upside: +601.75%
Merus
Aug 8, 2023
Maintains: Buy
Price Target: $46 → $48
Current: $41.90
Upside: +14.56%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $72.70
Upside: -22.97%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $4.20
Upside: +423.81%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $4.48
Upside: +480.36%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $18.84
Upside: +69.90%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $12.46
Upside: +12.36%